ITT analysis is highly desirable unless:■ there is overwhelming justification for a different
analysis policy (eg, an unacceptably high proportion of ineligible participants—those without …

Aims Recent randomized trials demonstrated a benefit of low-dose colchicine added to
guideline-based treatment in patients with recent myocardial infarction or chronic coronary …

There is a global diabetes epidemic correlating with an increase in obesity. This coincidence
may lead to a rise in the prevalence of type 2 diabetes. There is also an as yet unexplained …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …

Background Laser treatment for diabetic retinopathy is often associated with visual field
reduction and other ocular side-effects. Our aim was to assess whether long-term lipid …

Background Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to
assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3 …

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …

Background LDL cholesterol is a well established risk factor for atherosclerotic
cardiovascular disease. How much one should or safely can lower this risk factor remains …

Background: Lipoprotein (a)[Lp (a)] may play a causal role in atherosclerosis. PCSK9
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …

Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …